Bacille Calmette-Guérin

ApprovedBiologic

Bacille Calmette-Guérin is one of 108 biologic programs targeting Respiratory tract infection. It is currently in Approved.

Indications

Total Trials

Active Trials

107

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

Bladder CancerActive, not recruiting

COVID-19Active, not recruiting

Respiratory Tract InfectionApproved

Active, not recruiting

Bladder CancerPhase 1/Phase 2

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bacille Calmette-Guérin

Roche

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Singulair

AstraZeneca

Preclinical

1 7

Stivarga

Bayer

Preclinical

1 8

Aimovig

Amgen

Preclinical

1 9

Aldactone

Pfizer

Preclinical

1 10

Nexavar

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Terminated· Roche logo

Roche·Phase 1/2·NCT02792192·24 enrolled

Respiratory tract infection1 trial

Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults

Completed·UUMC Utrecht·Phase 4·NCT04537663·6,112 enrolled

COVID-191 trial

BCG Vaccination for Healthcare Workers in COVID-19 Pandemic

Completed·TTASK Applied Science·Phase 3·NCT04379336·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Bacille Calmette-Guérin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bacille Calmette-Guérin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bacille Calmette-Guérin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Roche

Bacille Calmette-Guérin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bladder Cancer1 trial

Respiratory tract infection1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News